Phase 3 in Focus - Ampreloxetine, Theravance Biopharma

Kevin McFarthing; Neha Prakash; Tanya Simuni

doi:10.3233/JPD-219004

Phase 3 in Focus - Ampreloxetine, Theravance Biopharma

Kevin McFarthing, Neha Prakash, Tanya Simuni

Neurology

Research output: Contribution to journal › Review article › peer-review

Original language	English (US)
Pages (from-to)	391-393
Number of pages	3
Journal	Journal of Parkinson's disease
Volume	11
Issue number	2
DOIs	https://doi.org/10.3233/JPD-219004
State	Published - 2021

ASJC Scopus subject areas

Clinical Neurology
Cellular and Molecular Neuroscience

Access to Document

10.3233/JPD-219004

Cite this

@article{9386e03d42224aa5a4f163e67dafa8bc,

title = "Phase 3 in Focus - Ampreloxetine, Theravance Biopharma",

author = "Kevin McFarthing and Neha Prakash and Tanya Simuni",

year = "2021",

doi = "10.3233/JPD-219004",

language = "English (US)",

volume = "11",

pages = "391--393",

journal = "Journal of Parkinson's Disease",

issn = "1877-7171",

publisher = "IOS Press",

number = "2",

}

TY - JOUR

T1 - Phase 3 in Focus - Ampreloxetine, Theravance Biopharma

AU - McFarthing, Kevin

AU - Prakash, Neha

AU - Simuni, Tanya

PY - 2021

Y1 - 2021

UR - http://www.scopus.com/inward/record.url?scp=85104303504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104303504&partnerID=8YFLogxK

U2 - 10.3233/JPD-219004

DO - 10.3233/JPD-219004

M3 - Review article

C2 - 33749621

AN - SCOPUS:85104303504

SN - 1877-7171

VL - 11

SP - 391

EP - 393

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

IS - 2

ER -

Phase 3 in Focus - Ampreloxetine, Theravance Biopharma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this